Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;80(12):1377-1379.
doi: 10.1001/jamaneurol.2023.3956.

Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Patrick Lipps  1   2   3 , Ana Beatriz Ayroza Galvão Ribeiro Gomes  1   2   3 , Laila Kulsvehagen  1   2   3 , Matthias Anthony Mutke  4 , Jens Kuhle  1   2   3 , Athina Papadopoulou  1   3   5 , Anne-Katrin Pröbstel  1   2   3
Affiliations

Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Patrick Lipps et al. JAMA Neurol. .
No abstract available

Plain language summary

This cross-sectional study examines whether proposed myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) diagnostic criteria can exclude other diseases, such as multiple sclerosis, and rely on results of cell-based assays.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Lipps reported receiving grants from Goldschmidt-Jacobson Stiftung during the conduct of the study and a European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) travel grant outside the submitted work. Dr Ayroza Galvão Ribeiro Gomes reported receiving grants (paid to the University of Sao Paulo for the collection and shipment of samples) from Roche, an ECTRIMS Clinical Fellowship, and a Swiss Government Excellence Scholarship during the conduct of the study. Ms Kulsvehagen reported receiving other from the Amsterdam University Fund. Dr Kuhle reported receiving grants from Swiss Multiple Sclerosis (MS) Society, Swiss National Research Foundation, Novartis, Biogen, Merck, Bristol Myers Squibb, Roche, and Sanofi outside the submitted work. Dr Papadopoulou reported receiving grants from University of Basel, University Hospital of Basel, Swiss MS Society, Swiss National Science Foundation (SNSF), and Freie Akademische Gesellschaft Basel during the conduct of the study and other from Sanofi-Genzyme, Eli Lilly, Abbvie, Lundbeck, Teva Pharmaceuticals, Hoffmann-La Roche, and Bayer AG outside the submitted work. Dr Pröbstel reported receiving grants from SNSF, National MS Society, Propatient Foundation, Fondation Pierre Mercier pour la Science, Goldschmidt Jacobson Foundation, and Gottfried and Julia Bangerter Rhyner Foundation during the conduct of the study and other from Biogen, Roche, and Novartis outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Myelin Oligodendrocyte Glycoprotein (MOG)–IgG Results With 2 Independent Cell-Based Assays (CBAs)
Gray areas with dotted lines indicate low-positive range of the fixed CBA (≥1:10 to <1:100) and live CBA (≥2.4 to <3.0); orange, final diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD); dark blue, final diagnosis distinct from MOGAD; and light blue, discordant final diagnosis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Marignier R, Hacohen Y, Cobo-Calvo A, et al. . Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20(9):762-772. doi:10.1016/S1474-4422(21)00218-0 - DOI - PubMed
    1. Banwell B, Bennett JL, Marignier R, et al. . Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282. doi:10.1016/S1474-4422(22)00431-8 - DOI - PubMed
    1. Ayroza Galvão Ribeiro Gomes AB, Kulsvehagen L, Lipps P, et al. . Immunoglobulin A antibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with central nervous system demyelination. JAMA Neurol. 2023;80(9):989-995. doi:10.1001/jamaneurol.2023.2523 - DOI - PMC - PubMed
    1. Thompson AJ, Banwell BL, Barkhof F, et al. . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2 - DOI - PubMed

Publication types